AGS-16C3F

· Astellas Pharma Global Development, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for AGS-16C3F, covering 2020-09-23 to 2024-11-01. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology [Phase 1]

See pricing